IMG-EN-AS-71155-01.jpg
Assay-kits

SensoLyte® 520 MMP-9 Assay Kit Fluorimetric - 1 kit

$554.00
Check your price
  • Cat.Number : AS-71155
  • Availability :
    In stock
  • Shipping conditions : Ice fees will apply

Alternative choices

Quantity

Add to wishlist Bulk Quote

MMP-9 (gelatinase-B, collagenase-IV) is involved in quite a few diseases such as a cancer, angiogenesis, alopecia and metastasis.
SensoLyte® 520 MMP-9 Assay Kit uses a 5-FAM (fluorophore) and QXL520™ (quencher) labeled FRET peptide substrates for continuous measurement of the enzyme activities. In an intact FRETpeptide, the fluorescence of 5-FAM is quenched by QXL520™. Upon the cleavage of the FRET peptide by MMP-9, the fluorescence of 5-FAM is recovered, and can be continuously monitored at excitation/emission = 490 nm/520 nm. With superior fluorescence quantum yield and longer emission wavelength, 5-FAM/QXL520™ based FRET peptide is less interfered by the autofluorescence of test compounds and cellular components and provides better assay sensitivity.
Members of the MMP family have poor substrate sequence specificity, making it difficult to use a peptide substrate alone to differentiate the activity of a particular MMP from other MMPs. If several MMPs are coexisting in your samples and you would like to specifically measure MMP-9 activity, please choose the SensoLyte® Plus MMP-9 Assay Kit, Cat# AS-72017.

Specifications

Packaging
Kits components
  • Component A: MMP-9 substrate 5-FAM/QXL™520 FRET peptide Ex/Em=490 nm/520 nm upon cleavage: 60 µL Component B: 5-FAM-Pro-Leu-OH, Fluorescence reference standard Ex/Em=490 nm/520 nm: 1 mM, 10 µL Component C: APMA, 4-aminophenylmercuric acetate: 1 M, 20 µL Component D: Assay buffer: 20 mL Component E: Stop solution: 10 mL
Chemistry
UniProt number
  • P14780
Properties
Absorbance (nm)
  • 490
Emission (nm)
  • 520
Storage & stability
Storage Conditions
  • Store all components at -20°C. Protect components A and B from light. Components D and E can be stored at 4 °C for convenience.
Activity
Application
Biomarker Target
Detection Method
Detection Limit
  • 0.2 ng/ml
Research Area
Sub-category Research Area
Usage
  • Research use

Downloads

You may also be interested in the following product(s)

IMG-EN-AS-60431-1-01.jpg

ADAMTS-4/Aggrecanase FRET Substrate, WAAG-3R - 1 mg

Cat.Number : AS-60431-1
$296.00 Excl. Tax
IMG-EN-AS-55576-1-01.jpg

MMP-9 (Catalytic Domain), human recombinant

Cat.Number : AS-55576-1
$119.00 Excl. Tax

Citations

Inhibition of matrix metalloproteinases prevents the potentiation of nondeprived-eye responses after monocular deprivation in juvenile rats

Cereb Cortex . 2011 Jun 17 ; 22(3) 725-34 | DOI : 10.1093/cercor/bhr158

  • M. Spolidoro

Association of the MMP9 gene with childhood cedar pollen sensitization and pollinosis

J Hum Genet . 2012 Jan 12 ; 57 176 | DOI : 10.1038/jhg.2011.148

  • H. Inoue

Intracerebroventricular administration of an endothelin ETB-receptor agonist increases expression of matrix metalloproteinase-2 and -9 in rat brain

Neuroscience . 2007 Jun 06 ; 147 620 | DOI : 10.1016/j.neuroscience.2007.04.047

  • Y. Koyama

Rhodamine derivatives as selective protease inhibitors against bacterial toxins

Chem Biol Drug Des . 2008 Jan 19 ; 71 131 | DOI : 10.1111/j.1747-0285.2007.00617.x

  • S.L. Johnson

Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein

Eur Respir J . 2008 Mar 05 ; 32 405 | DOI : 10.1183/09031936.00173207

  • O. Soehnlein

A novel pharmacophore model for the design of anthrax lethal factor inhibitors

Chem Biol Drug Des . 2010 Sep 01 ; 76 263 | DOI : 10.1111/j.1747-0285.2010.01000.x

  • H. Yuan

A high-throughput screening approach to anthrax lethal factor inhibition

Bioorg Chem . 2007 Feb 22 ; 35 306 | DOI : 10.1016/j.bioorg.2006.12.005

  • S.L. Johnson

Matrix metalloproteinase content and activity in low-platelet, low-leukocyte and high-platelet, high-leukocyte platelet rich plasma (PRP) and the biologic response to PRP by human ligament fibroblasts.

Am J Sports Med . 2014 Mar 13 ; 42(5) 1211 | DOI : 10.1177/0363546514524710

  • M.A. Pifer

Urine matrix metalloproteinases (MMPs) as biomarkers for the progression of fracture healing.

Injury . 2012 Mar 01 ; 43(3) 274 | DOI : 10.1016/j.injury.2011.05.038

  • N.A. Wigner

Suramin enhances the urinary excretion of VEGF-A in normoglycemic and streptozotocin-induced diabetic rats

Pharmacol Rep. . 2021 Feb 26 ; 73(3) 841 | DOI : https://doi.org/10.1007/s43440-021-00236-0

  • G. Chyła
  • et al

Prolyl Endopeptidase Gene Disruption Improves Gut Dysbiosis and Non-alcoholic Fatty Liver Disease in Mice Induced by a High-Fat Diet

Front Cell Dev Biol . 2021 May 20 ; 9 628143 | DOI : 10.3389/fcell.2021.628143

  • D. Jiang
  • et al

Maternal Glucocorticoids Make the Fetal Membrane Thinner: Involvement of Amniotic Macrophages

Endocrinol. . 2019 Apr 01 ; 160(4) 925 | DOI : https://doi.org/10.1210/en.2018-01039

  • H. Kiyokawa
  • et al

Nucleic acid-induced potentiation of matrix metalloproteinase-9 enzymatic activity

Biochem J . 2018 May 09 ; 475(9) 1597 | DOI : https://doi.org/10.1042/BCJ20180035

  • T. Duellman
  • et al

Melatonin Preserves Blood-Brain Barrier Integrity and Permeability via Matrix Metalloproteinase-9 Inhibition

PLoS One . 2016 May 06 ; 11(5) e0154427 | DOI : https://doi.org/10.1371/journal.pone.0154427

  • H. Alluri
  • et al

Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling

Oncol Rep . 2014 Oct 14 ; 2(6) 2557 | DOI : https://doi.org/10.3892/or.2014.3547

  • J. Wang
  • et al